Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

69.02
Delayed Data
As of Jul 31
 -0.05 / -0.07%
Today’s Change
47.36
Today|||52-Week Range
72.31
+20.01%
Year-to-Date
Will Teva (TEVA) Stock be Helped by New Financing Commitment?
Jul 31 / TheStreet.com
Will McKesson (MCK) Keep the Earnings Streak Alive? - Analyst Blog
Jul 27 / Zacks.com
Teva Pharmaceutical Industries Ltd. Beats The Street in the Second Quarter: What's Ne...
Jul 31 / MotleyFool.com
3 Health Care Stocks to Trade for Gains
Jul 27 / TheStreet.com
Israel ETFs Surge on Teva Megamerger Deal (revised) - ETF News And Commentary
Jul 31 / Zacks.com
Tread Carefully in the Market
Jul 27 / TheStreet.com
Teva's Q2 Earnings & Revenues Beat Expectations, View Up - Analyst Blog
Jul 31 / Zacks.com
Cramer's Charitable Trust: We Love This Possible Allergan Deal
Jul 27 / TheStreet.com
The Tale of Two Teva Pharmaceuticals
Jul 30 / MotleyFool.com
Teva Pharmaceutical to Buy Allergan's Generics Unit in $40.5 Billion Deal - Stocks in...
Jul 27 / Zacks.com
Teva Pharmaceutical (TEVA) Earnings Report: Q2 2015 Conference Call Transcript
Jul 30 / TheStreet.com
Why Mylan N.V. Stock Slumped Today
Jul 27 / MotleyFool.com
Teva (TEVA) Beats on 2Q Earnings & Revenues, Raises Outlook - Tale of the Tape
Jul 30 / Zacks.com
Stocks Hitting 52-Week Highs
Jul 27 / Benzinga
What to Expect from Exelixis (EXEL) This Earnings Season? (revised) - Analyst Blog
Jul 29 / Zacks.com
Why Teva Pharmaceutical Industries Ltd. Stock Jumped Today
Jul 27 / MotleyFool.com
Teva to Buy Allergan's Generics Business for $40.5B - Analyst Blog
Jul 28 / Zacks.com
Teva Pharmaceuticals (TEVA) Stock Climbing on Allergan Generic Drug Business Purchase
Jul 27 / TheStreet.com
What to Expect from Exelixis (EXEL) This Earnings Season? - Analyst Blog
Jul 28 / Zacks.com
Benzinga's Top #PreMarket Gainers
Jul 27 / Benzinga
Israel ETFs Surge on Teva Megamerger Deal - ETF News And Commentary
Jul 28 / Zacks.com
China Tanks as Q2 Marches On - Ahead of Wall Street
Jul 27 / Zacks.com
Hikma Pharmaceuticals to Buy Generic Drug Maker Roxane for $2.65 Billion
Jul 28 / TheStreet.com
US Stock Futures Signal Lower Start On Wall Street
Jul 27 / Benzinga
Will Teva Pharmaceutical (TEVA) Stock Rise Following BMO Capital Upgrade?
Jul 28 / TheStreet.com
Teva buys Allergan's generic drugs business for $40.5 billion
Jul 27 / CNNMoney.com
New Lifetime High Reached: Teva Pharmaceutical Industries (TEVA)
Jul 28 / TheStreet.com
Teva Pharmaceutical Industries (TEVA): Heavy Pre-Market Activity
Jul 27 / TheStreet.com
Watching Twitter for Moves at Teva and Biogen
Jul 28 / TheStreet.com
Chinese Stocks Post Biggest One-Day Loss in Eight Years
Jul 27 / TheStreet.com
Health Care & Industrials: Two ETFs Trading with Outsized Volume - ETF News And Comme...
Jul 28 / Zacks.com
Stocks: 5 things to know before the open
Jul 27 / CNNMoney.com
Benzinga's M&A Chatter for Monday July 27, 2015
Jul 27 / Benzinga
Futures Start Mixed with Fed and GDP on Tap
Jul 26 / TheStreet.com
Mylan Shares Tank After Teva Pharmaceutical Nixes Takeover Bid
Jul 27 / TheStreet.com
Will Express Scripts (ESRX) Miss Earnings Estimates in Q2? - Analyst Blog
Jul 24 / Zacks.com
Will Currency & Generics Weigh on Pfizer (PFE) Q2 Earnings? - Analyst Blog
Jul 27 / Zacks.com
Will Merck (MRK) Pull a Surprise this Earnings Season? - Analyst Blog
Jul 24 / Zacks.com
Cramer -- Twitter Has Short-Term Problems; Gilead's 'Problem' Is Too Much Cash
Jul 27 / TheStreet.com
Biogen Tops Q2 Earnings, Cuts View on Tecfidera Issues - Analyst Blog
Jul 24 / Zacks.com
Allergan CEO: Teva Made A 'Compelling Offer' We Couldn't Refuse
Jul 27 / Benzinga
Will Biogen (BIIB) Surprise in 2Q Despite Tecfidera Issues? - Analyst Blog
Jul 23 / Zacks.com
Stocks Down in the Dumps as Chinese Market Slumps
Jul 27 / TheStreet.com